"Moderna's Stock Soars on CEO's 2025 Sales Forecast and Oppenheimer Upgrade"
Moderna's stock surged nearly 14% following an upgrade to "outperform" by Oppenheimer and reaffirmation of its 2025 sales growth target by CEO Stéphane Bancel. Despite a significant drop in share value in 2023 due to declining COVID-19 vaccine sales, the company is optimistic about the upcoming launch of its RSV vaccine and a flu/COVID combination vaccine. Moderna aims to have five products on the market by 2026 and to break even financially by that year, with projected revenues of $4 billion in 2024 from its COVID and RSV vaccines.